Cardiff Oncology
CRDFCardiff Oncology is a clinical-stage biotechnology company focused on developing novel cancer therapies by targeting Polo-like Kinase 1 (PLK1).
Table of contents
Earnings
Next report
Aug 4, 2026 (In 3 weeks)Competitors
By market cap
By revenue growth
Profile
Cardiff Oncology is a clinical-stage biotechnology company focused on developing novel cancer therapies by targeting Polo-like Kinase 1 (PLK1). The company leverages its lead oral selective inhibitor, onvansertib, in combination with standard-of-care treatments to address tumor vulnerabilities in hard-to-treat cancers. Their development strategy integrates tumor genomics and biomarker assays to optimize patient selection and therapeutic response monitoring.
A clinical-stage developer focusing on a highly selective PLK1 inhibition strategy to overcome resistance in RAS-mutated and other difficult-to-treat cancers.
Questions, answered.
- What is Cardiff Oncology's market cap?
- Cardiff Oncology (CRDF) has a market capitalization of $90.2M and trades on NASDAQ.
- Who are Cardiff Oncology's competitors?
- Cardiff Oncology's key competitors include Amgen Inc., Immunome, Inc., Nuvation Bio Inc., and others. These companies compete in similar markets and product categories.
- Where is Cardiff Oncology headquartered?
- Cardiff Oncology is headquartered in United States of America and employs approximately 32 people. It has been publicly traded since 1997.